Summary
64 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 EUR of revenue, 10 EUR is left as free cash.
What to watch
- Revenue grew by only 0.5% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 10.3 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 8.8% a year over 5 years. Over the last 3 years it grew by 0.5% a year. For the next fiscal year analysts expect revenue to grow by 9.2%. Earnings per share fell by 0.4% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 61 EUR
- Research and development 8.9 EUR
- Sales and administration 16 EUR
- Taxes and other 4.4 EUR
- Net profit 10 EUR
Net profit, industry median (Medical - Devices) 6.9 EUR
Out of every 100 EUR of revenue, 10 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 2.59%
- Paid out of profit
- 27%
You receive $0.59 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.